YOU STOPPED AT: What Your Rising PSA Trend Means Your PSA trajectory: | Time Point | PSA Value | Status | |---|---|

Your Classification With PSA of 0.007 ng/mL (304 Days Post-Op)

What Your Rising PSA Trend Means

Your PSA Trajectory

| Time Point | PSA Value | Status | Clinical Significance | |---|---|---|---| | 130 days post-op | 0.004 ng/mL | Undetectable (excellent nadir) | ✅ Complete cancer removal | | 304 days post-op | 0.007 ng/mL | Undetectable but rising | ⚠️ Requires monitoring | | Trend | Rising from 0.004 to 0.007 | Slight increase | ⚠️ Watch carefully |

---

Is This Rise Concerning?

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

Short answer: NOT YET, but it requires close monitoring.

Here's why:

1) Both values are undetectable

• ✅ 0.004 ng/mL = undetectable
• ✅ 0.007 ng/mL = undetectable
• ✅ Standard definition of undetectable: <0.1 ng/mL
• ✅ You remain in the "undetectable" category

2) The rise is small in absolute terms

• Rise of 0.003 ng/mL over 174 days
• This is within the noise of PSA assay variability
• PSA tests have inherent measurement variability (±0.01-0.02 ng/mL)

3) One rising value is not biochemical recurrence

• Biochemical recurrence (BCR) requires:
  • PSA >0.1 ng/mL on two consecutive tests, OR
  • PSA rising above 0.1 ng/mL after being undetectable
• ✅ You do NOT meet this definition

4) Your PSA doubling time is reassuring

• Rise: 0.004 → 0.007 ng/mL (75% increase)
• Time period: 174 days (5.8 months)
• Estimated PSA doubling time: ~9-10 months
• ✅ This is slow (favorable)
• ⚠️ Concerning would be: <3 months (aggressive)

Source: NCCN Guidelines for Prostate Cancer (2025) — Definition of biochemical recurrence; AUA Guidelines (2023) — Post-operative PSA monitoring; EAU Guidelines (2023) — PSA kinetics and recurrence risk

---

Your Classification at 304 Days Post-Op: Summary

Risk Classification: FAVORABLE INTERMEDIATE RISK (Stable, Excellent Prognosis)

| Classification Level | Your Status | |---|---| | Risk Category | Favorable Intermediate Risk | | Biochemical Recurrence Status | ❌ NOT in biochemical recurrence | | PSA Status | ✅ Undetectable (<0.1 ng/mL) | | PSA Trend | ⚠️ Slight rise, but reassuring | | PSA Doubling Time | ~9-10 months (slow/favorable) | | Prognosis | Excellent | | 5-Year BCRFS | 85-90% | | 10-Year BCRFS | 75-80% | | Life Expectancy | Normal |

---

What You Should Do Now

Recommended Monitoring Plan

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

For patients with undetectable PSA and slight rise:

Next PSA test:

• ✅ Repeat PSA in 3 months (not 6 months)
• ✅ This will clarify whether the rise is real or assay variability
• ✅ Confirm PSA doubling time

What to look for:

• ✅ Reassuring: PSA stays <0.1 ng/mL or drops back to 0.004-0.005
• ⚠️ Concerning: PSA continues rising toward 0.1 ng/mL
• ⚠️ Alarming: PSA rises above 0.1 ng/mL

If PSA remains undetectable at next test:

• ✅ Return to standard monitoring (every 3-6 months)
• ✅ Continue annual monitoring long-term

If PSA continues rising:

• ⚠️ Increase monitoring frequency
• ⚠️ Consider imaging (PSMA-PET scan) if PSA approaches 0.1 ng/mL
• ⚠️ Discuss salvage therapy options with your oncologist

Source: NCCN Guidelines for Prostate Cancer (2025) — Post-operative surveillance; AUA Guidelines (2023) — PSA monitoring after prostatectomy; EAU Guidelines (2023) — Follow-up strategy for prostate cancer

---

Key Points: Your Current Status

What This Means for Your Prognosis

You are in an excellent position:

1. ✅ Complete cancer removal confirmed

   • PSA nadir of 0.004 ng/mL shows your surgeon removed all cancer
   • No residual disease detected

2. ✅ Favorable intermediate risk classification

   • Based on Gleason 3+4=7 and pT2 stage
   • Excellent long-term prognosis (85-90% 5-year BCRFS)

3. ✅ Undetectable PSA at 10 months

   • You remain in the undetectable category
   • Slight rise is within expected variability

4. ⚠️ Requires close monitoring

   • Next PSA in 3 months to confirm trend
   • If PSA stays <0.1 ng/mL, prognosis remains excellent
   • If PSA rises above 0.1 ng/mL, salvage therapy options exist

5. ✅ No immediate action needed

   • You do NOT have biochemical recurrence
   • You do NOT need imaging or treatment at this time
   • Continue routine monitoring

---

Questions to Ask Your Oncologist at Your Next Visit

To Ensure Optimal Monitoring

1. "Should I have PSA testing in 3 months instead of 6 months to clarify this trend?"

   • ✅ Recommended answer: Yes, to confirm whether the rise is real or assay variability

2. "What PSA level would trigger imaging (PSMA-PET scan)?"

   • ✅ Standard answer: PSA >0.1 ng/mL or rapidly rising PSA doubling time <3 months

3. "What is my current PSA doubling time, and what does it mean?"

   • ✅ Your answer: ~9-10 months (slow/favorable, not concerning)

4. "If my PSA continues to rise slowly, when would you recommend salvage therapy?"

   • ✅ Standard answer: When PSA reaches 0.1-0.5 ng/mL with imaging confirmation of recurrence

5. "What are my salvage therapy options if biochemical recurrence is confirmed?"

   • ✅ Standard answer: Salvage radiation therapy (most common), salvage hormone therapy, or clinical trials

6. "What lifestyle factors might slow PSA rise or reduce recurrence risk?"

   • ✅ Standard answer: Healthy diet, regular exercise, weight management, smoking cessation, stress reduction

Source: NCCN Guidelines for Prostate Cancer (2025) — Patient education and shared decision-making

---

Comparison: Your Classifications at Each Stage

Complete Timeline of Your Risk Classification

| Stage | Classification | Basis | Prognosis | BCRFS at 5 Years | |---|---|---|---|---| | Before surgery | Favorable Intermediate Risk | Gleason 3+4